BONESUPPORT Data Underscore CERAMENT G’s Role in Infection Prevention for Severe Fractures

BONESUPPORT HOLDING AB ( (SE:BONEX) ) just unveiled an announcement.

BONESUPPORT has reported new U.S. clinical data demonstrating the potential of its CERAMENT G bone graft substitute in reducing infection risk for trauma patients undergoing intramedullary nailing for severe open long-bone fractures. In a single-center case series at HCA Florida Kendall Hospital, nine patients with high-risk open tibia, femur, or humerus fractures treated with CERAMENT G via the Flow-FX 2-CAN device achieved fracture union without fracture-related infections, amputations, or infection-related reoperations over an average 9.1-month follow-up.

The authors of the OTA International publication concluded that augmenting intramedullary nails with CERAMENT G offers a time-efficient, technically straightforward approach to local antibiotic prophylaxis in complex open fractures. The results, while based on a small cohort, strengthen BONESUPPORT’s growing U.S. evidence base and support the company’s strategic positioning in infection prevention and bone healing solutions for high-risk orthopedic trauma cases.

The most recent analyst rating on (SE:BONEX) stock is a Buy with a SEK220.00 price target. To see the full list of analyst forecasts on BONESUPPORT HOLDING AB stock, see the SE:BONEX Stock Forecast page.

More about BONESUPPORT HOLDING AB

BONESUPPORT is a Swedish orthobiologics company listed on Nasdaq Stockholm that develops and commercializes innovative injectable bio-ceramic bone graft substitutes, marketed under the CERAMENT brand. Its products are designed to remodel into the patient’s own bone and can locally elute drugs, with a focus on improving clinical and health economic outcomes in the management of complex bone injuries.

Average Trading Volume: 302,596

Technical Sentiment Signal: Buy

Current Market Cap: SEK13.29B

See more data about BONEX stock on TipRanks’ Stock Analysis page.